Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity

Paraoxonase (PON1) is an A-esterase capable of hydrolysing the active metabolites (oxons) of a number of organophosphorus (OP) insecticides such as parathion, diazinon and chlorpyrifos. PON1 activity is highest in liver and plasma, and among animal species significant differences exist, with birds and rabbits displaying very low and high activity, respectively. Human PON1 has two polymorphisms in the coding region (Q192R and L55M) and five polymorphisms in the promoter region. The Q192R polymorphism imparts different catalytic activity toward some OP substrates, while the polymorphism at position -108 (C/T) is the major contributor to differences in the level of PON1 expression. Animal studies have shown that PON1 is an important determinant of OP toxicity, with animal species with a low PON1 activity having an increased sensitivity to OPs. Administration of exogenous PON1 to rats or mice protects them from the toxicity of OPs. PON1 knockout mice display a high sensitivity to the toxicity of diazoxon and chlorpyrifos oxon, but not paraoxon. In vitro assayed catalytic efficiencies of purified PON192 isoforms for hydrolysis of specific oxon substrates accurately predict the degree of in vivo protection afforded by each isoform. Low PON1 activity may also contribute to the higher sensitivity of newborns to OP toxicity.

[1]  R. Fenske,et al.  Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. , 1997, Journal of toxicology and environmental health.

[2]  A. Main.  The role of A-esterase in the acute toxicity of paraoxon, TEPP, and parathion. , 1956, Canadian journal of biochemistry and physiology.

[3]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[4]  I. Leviev,et al.  The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients , 2001, Diabetologia.

[5]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[6]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[7]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[8]  S. D. Murphy,et al.  The influence of age on the toxicity and metabolism of methyl parathion and parathion in male and female rats. , 1975, Toxicology and applied pharmacology.

[9]  W. Kalow.  Pharmacogenetics and evolution , 2000 .

[10]  J. Chambers,et al.  Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. , 1995, Toxicology letters.

[11]  A. Moretto,et al.  Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks. , 1991, Biochemical pharmacology.

[12]  G. Omenn,et al.  Species Differences in Serum Paraoxonase Correlate with Sensitivity to Paraoxon Toxicity , 1987 .

[13]  T. Slotkin,et al.  Chlorpyrifos exposure during a critical neonatal period elicits gender-selective deficits in the development of coordination skills and locomotor activity. , 2000, Brain research. Developmental brain research.

[14]  V. Moser,et al.  Comparison of the role of esterases in the differential age-related sensitivity to chlorpyrifos and methamidophos. , 2000, Neurotoxicology.

[15]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[16]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[17]  M. Hooper,et al.  Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. , 1996, Journal of biochemical toxicology.

[18]  L. Costa,et al.  Paraoxonase protects against chlorpyrifos toxicity in mice. , 1995, Toxicology letters.

[19]  L. Costa.  Basic toxicology of pesticides. , 1997, Occupational medicine.

[20]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[21]  C. Disteche,et al.  Paraoxonase (PON1) gene in mice: sequencing, chromosomal localization and developmental expression. , 1997, Pharmacogenetics (London).

[22]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[23]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[24]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[25]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[26]  L. Sheets.  A consideration of age-dependent differences in susceptibility to organophosphorus and pyrethroid insecticides. , 2000, Neurotoxicology.

[27]  E. Schwartz,et al.  Gln → Arg 191 Polymorphism of Paraoxonase and Parkinson’s Disease , 1999, Human Heredity.

[28]  J. Joven,et al.  Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. , 2001, Metabolism: clinical and experimental.

[29]  Z. Liu,et al.  No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population , 2000, Movement disorders : official journal of the Movement Disorder Society.

[30]  K. Augustinsson,et al.  AGE VARIATION IN PLASMA ARYLESTERASE ACTIVITY IN CHILDREN. , 1963, Clinica chimica acta; international journal of clinical chemistry.

[31]  P. Stetson,et al.  Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* , 2000, The Journal of Biological Chemistry.

[32]  A. Motulsky,et al.  Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. , 1983, American journal of human genetics.

[33]  Y. Ikeda,et al.  Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. , 2000, Metabolism: clinical and experimental.

[34]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[35]  R. Haley,et al.  Gene therapy to prevent organophosphate intoxication. , 2001, Toxicology and applied pharmacology.

[36]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[37]  S. Scherer,et al.  Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. , 1998, Gene.

[38]  P. Durrington,et al.  Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.

[39]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[40]  D. Shih,et al.  CHD and Atherosclerosis: Human Epidemiological Studies and Transgenic Mouse Models , 2002 .

[41]  R. Humbert,et al.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. , 1991, Biochemistry.

[42]  J. Miller,et al.  Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.

[43]  C. Pope,et al.  Age-related differences in sensitivity to organophosphorus pesticides. , 1997, Environmental toxicology and pharmacology.

[44]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[45]  L. Costa,et al.  Serum paraoxonase status: a major factor in determining resistance to organophosphates. , 1993, Journal of toxicology and environmental health.

[46]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[47]  The emerging field of ecogenetics. , 2000, Neurotoxicology.

[48]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[49]  Naoki Masuda,et al.  Sarin poisoning in Tokyo subway , 1995, The Lancet.

[50]  Y. Ikeda,et al.  A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.

[51]  S. Khuder,et al.  Environmental risk factors and Parkinson's disease: a metaanalysis. , 2001, Environmental research.

[52]  T. Diepgen,et al.  The human serum paraoxonase—Polymorphism and specificity , 1988 .

[53]  E. Schwartz,et al.  Paraoxonase 1 Met–Leu 54 polymorphism is associated with Parkinson’s disease , 2001, Journal of the Neurological Sciences.

[54]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[55]  A. Tward,et al.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. , 2000, Pharmacogenetics.

[56]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[57]  C. Walker,et al.  A‐esterase activities in relation to the differential toxicity of pirimiphos‐methyl to birds and mammals , 1980 .

[58]  I. Kondo,et al.  Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease , 1998, Brain Research.

[59]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[60]  G. Omenn,et al.  Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. , 1990, Toxicology and applied pharmacology.

[61]  C. Furlong,et al.  Purification of rabbit and human serum paraoxonase. , 1991, Biochemistry.

[62]  T. Yoshikawa,et al.  Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. , 2001, American journal of ophthalmology.

[63]  B. Eskenazi,et al.  Exposures of children to organophosphate pesticides and their potential adverse health effects. , 1999, Environmental health perspectives.